Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 37Prostatic Neoplasms 12Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 3Fibrosis 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Intraductal, Noninfiltrating 3Uterine Cervical Neoplasms 2Thyroid Nodule 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma 2Lymphedema 2Leukemia, Myeloid, Acute 2Leukemia 2Inflammatory Breast Neoplasms 2Infertility 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Anatomic Stage III Breast Cancer AJCC v8 2

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × High-Energy Shock Waves × Clear all
NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

University of Southern California

Phase 1 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

M.D. Anderson Cancer Center

Phase NA Active not recruiting
798 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡